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By the use of in vivo imaging, we investigated the dynamics of estrogen receptor (ER) activity in
intact, ovariectomized, and hormone-replaced estrogen response element-luciferase reporter
mice. The study revealed the existence of a long-paced, noncircadian oscillation of ER transcrip-
tional activity. Among the ER-expressing organs, this oscillation was asynchronous and its ampli-
tude and periodwere tissue dependent. Ovariectomy affected the amplitude but did not suppress
ER oscillations, suggesting the presence of tissue endogenous oscillators. Long-term administra-
tion of raloxifene, bazedoxifene, combined estrogens alone or with basedoxifene to ovariecto-
mized estrogen response element-luciferase mice showed that each treatment induced a distinct
spatiotemporal profile of ER activity, demonstrating that the phasing of ER activity among tissues
maybe regulatedby the chemical nature and the concentrationof circulatingestrogen. This points
to the possibility of a hierarchical organization of the tissue-specific pacemakers. Conceivably, the
rhythmof ER transcriptional activity translates locally into the activation of specific gene networks
enabling ER to significantly change its physiological activity according to circulating estrogens. In
reproductive and nonreproductive organs this hierarchical regulation may provide ER with the
signaling plasticity necessary to drive the complex metabolic changes occurring at each female
reproductive status. We propose that the tissue-specific oscillatory activity here described is an
important component of ER signaling necessary for the full hormone action including the
beneficial effects reported for nonreproductive organs. Thus, this mechanism needs to be
taken in due consideration to develop novel, more efficacious, and safer hormone replacement
therapies. (Endocrinology 152: 2256–2265, 2011)
The normal aging process in women results in meno-pause, which is characterized by the cessation of ovar-
ian function and the decrease of sex hormone synthesis.
Among the most common effects associated with meno-
pause are vasomotor instability, loss of body mass, and
altered lipid profile; in addition, several epidemiological
studies indicated that after menopause there is a signifi-
cant increase of cardiovascular (1, 2), immune (3), skeletal
(4, 5), and central nervous system (6, 7) disorders, sug-
gesting a protective action of estrogens also in tissues not
directly associated with reproductive functions. The ex-
tension of the negative effects after the reduced synthesis
of estrogens may be explained by the lack of activation of
the two estrogen receptors (ER; ER and ER) because
ERs are expressed in most mammalian cells in which, by
controlling specific transcription programs, they are
deeply involved in the whole-cell metabolism (8).
Attempts to reinstate estrogen beneficial effects with
hormone replacement therapies (HRT)didnotprovide the
expected results so far. HRT has been carried out admin-
istering17-estradiol or conjugated estrogens (CE) tohys-
terctomized women; in nonhysterectomized women a
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combined therapy has been appliedwith progestagens op-
posing the hyperplastic effects of estrogen therapy in the
uterus (9). To avoid estrogen unwanted effects on uterus
and mammary gland but retain their beneficial effects in
other organs efforts weremade to identify ER ligands able
to mimic the hormone activity in nonreproductive organs
and to antagonize its effects in the uterus and mammary
gland. Several such molecules, named selective estrogen
receptor modulators (SERM) in virtue of their tissue-se-
lective ER agonist or antagonist properties, were devel-
oped and entered clinical practice (10). To date, however,
none of the SERM developed appear to be provided with
the ideal balance of ER agonist and antagonist activity for
an optimal postmenopausal therapy (11). For instance,
the SERM used so far tend to be ER antagonists in the
central nervous system, thus accentuating menopause va-
somotor symptoms (11). To overcome these limitations, a
novel HRT concept was proposed, which consists in the
combination of natural estrogens with a SERM: in this
way the whole spectrum of ER agonists effects can be
obtained and the activity in the reproductive organs is
blocked. This HRT has been named tissue selective estro-
gen complex (TSEC) (12, 13).
In all cases, HRTs are carried out by the continuous
administration of the hormone aimed at maintaining a
constant level of circulating estrogens: this is in contrast
with the systemic, periodic fluctuations of ER activity due
to the changes of ovarian functions during the menstrual
cycle. The impact of continuous stimulation of a receptor
system developed to respond to oscillating levels of hor-
mone is unknown; thus, a better understanding of the pe-
riodic nature of ER signaling in the whole organism may
be an important factor for the generation of more effica-
cious HRT. The goal of the present study was to investi-
gate the effects of HRTs on the temporal organization of
ER transcriptional activity in reproductive and nonrepro-
ductive tissues. To this aim, we took advantage of the
estrogen response element (ERE)-luciferase (Luc) trans-
genic mouse characterized by the ubiquitous, ER-regu-
lated expression of the luciferase gene (14). In this animal
model, the possibility tomeasure luciferase activity in vivo
by bioluminescence-based imaging provides the opportu-
nity to investigate the ER systemic activity in time (14–
17).Herewe studied in amodel of surgicalmenopause the
extent to which current modalities of HRT, based on es-
trogens, SERM, and TSEC administration, were able to
restore the physiological oscillation occurring in healthy,
cycling mice (12, 13).
We show that in intact mice ER activity oscillates at a
pace that is similar in each tissue but is not always syn-
chronizedon estrogen synthesis in the ovaries. In addition,
our results demonstrate that, in each tissue, the continuous
administration of natural or synthetic estrogens induces
profiles of ERoscillationwith an amplitude and frequency
that are characteristic of each compound administered.
Because of that, upon hormone therapy (HT) the phasing of
ER activity among target organs may be significantly dis-
rupted compared with what is observed in healthy, cycling
mice. We propose that the decentralized ER oscillatory be-
haviorobserved in intactmicemight respondtoprecisephys-
iological needs and that the study of HT effects on ER oscil-
latory profile might provide a novel mean for the
identification of safer and more efficacious HRT.
Materials and Methods
Animal studies
In the present study, we used heterozygous C57BL/6
repTOPERE-Luc (Transgenic Operative Products srl, Lodi, Italy)
females 2–3 months of age (18). Mice were housed in individually
ventilated plastic cages with hardwood chip bedding and animal
house, fed ad libitum with a standard diet (4RF21 standard diet;
Mucedola, SettimoMilanese, Italy) and provided with filtered wa-
ter. The animal room was maintained within a temperature range
of22–25C,relativehumidityof5010%,andunderanautomatic
cycle of 12-h light, 12-h dark (lights on at 0700 h).
All animal experimentation was carried out in accordance
with the Guide for the Care and Use of Laboratory Animals as
adopted and promulgated by the U.S. National institutes of
Health and also in accordance with the European Guidelines for
Animal Care andUse of Experimental Animals, approved by the
ItalianMinistryofResearchandUniversity and controlledby the
panel of experts of the Department of Pharmacological Sciences
(University of Milan, Mila, Italy). Mice were ovariectomized 3
wk before the beginning of the study. Animals were assigned to
a specific experimental group and treated per os (gavage) for 6 h
(acute treatment) or daily for 21 d (chronic treatment) with ve-
hicle, CE (3mg/kg), bazedoxifen (BZA; 2 and10mg/kg), or BZA
in association with 3 mg/kg CE (TSEC) and raloxifen (RAL; 2
and 10 mg/kg). All compounds tested (Wyeth, Collegeville, PA)
were dissolved in dimethylsulfoxide and subsequently diluted in
vehicle (2% Tween 80 and 0.5% carboxymethylcellulose water
solution). Controls were treated with vehicle. Compounds were
administered always at 0930 h; the in vivo imaging session took
place at 1500 h.
In vivo imaging
Mice were injected ip with 80 mg/kg D-luciferin (beetle lu-
ciferin potassium salt; Promega, Madison, WI) 15 min before
each in vivo imaging session. Previous experiments had demon-
strated that this dose and time are sufficient to obtain an uniform
biodistribution of the substrate (19, 20).Mice were anesthetized
using isofluorane (Isofluorane-Vet; Merial, Lyon, France) and
Xenogen XGI-8 gas anesthesia system (Caliper Life Sciences,
Hopkinton, MA) and kept under anesthesia during the whole
imaging session [gas anesthesia system setting: vaporizer value
2.5%; oxygen flow 1.5 l/min in the induction chamber and 0.25
l/min to themiceduring the in vivo imaging in the charge-coupled
device (CCD) camera]. Photon emission in mice was measured
for 5-min-long periods using a CCD camera (Xenogen IVIS Lu-
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mina system; Caliper Life Sciences) consisting of a scientific-
grade thermoelectrically cooled CCD camera mounted on a
light-tight imaging chamber. Bioluminescence was measured
with tiff images of 512  512 pixels at 16 bits. Each pixel con-
tained the number of photon counts detected over the exposure
period at the resolution of about 0.3 pixels/mm. Instrumental
efficiency was measured with appropriate luminescent sub-
strates (Glowell; Lux Biotechnology, Edinburgh, UK).
Automatic analysis of mouse images:
segmentation algorithm
Anatomical areas (head, limbs, tail, reproductive area, he-
patic area, abdominal area) were segmented in Matlab environ-
ment (TOP Transgenic Operative Products srl) using an algo-
rithm previously described (21). The anatomical areas analyzed
were: skeletal areas (bone and limbs), reproductive areas (genital
andmammaryglands), andhepatic andabdominal areas. In each
anatomical area, photon emission was defined as the number of
photons (p) per second per centimeter squared corrected for in-
strument efficiency. All the measurements were in the linearity
range of the detector (IVIS Lumina; Caliper Life Sciences) and
were previously validated by the comparison with the manual
analysis carried out using the CCD camera software (Living Im-
age 3.0; Caliper Life Sciences).
Luciferase enzymatic assay
Tissues were homogenized in 200 l of lysis buffer (100 mM
KPO4; 1 mM dithiothreitol; 4 mM EGTA; 4 mM EDTA, pH 7.8)
with a 5-mm inox bead in a TissueLyser (QIAGEN GmbH,
Hilden, Germany), subjected to one freezing-thawing cycle, and
centrifuged for 30min at 4900 g at 4C (Allegra 25R; Beckman
Coulter, Brea, CA), and supernatants containing luciferase were
collected in ice. In samples containing luciferase, protein con-
centration was measured by the Bradford assay, following the
manufacturer’s instructions (Thermo Fisher Scientific Inc.,
Waltham, MA). Luciferase enzymatic activity was then assayed
with a commercial luciferase assay buffer (Promega). Light in-
tensity was measured with a luminometer (Glomax96 micro-
plate luminometer; Promega) andexpressedas relative lightunits
over 10 sec per microgram of proteins.
Vaginal smear
Vaginal smearswere carriedout at 0, 7, 14, and21dat 0900h
byvaginal flushingwith sterile physiological solution,whichwas
subsequently air dried on glass microscope slides and stained
with the May-Gru¨nwald and Giemsa methods (MGG Quick
stain kit,; Bio-Optica, Milan, Italy) following the protocol pro-
vided by the manufacturer.
Measurement of the phasing of ER oscillatory in
different body areas
The synchronicphasingofERactivitywas analyzedmanually
by counting each body area by the total number of peaks of ER
activity/mouse during the 21-d-long experiment and then the
number of coincident peaks for each couple of body areas. The
percentages of coincident/noncoincident peaks obtained from
the six to 10 individual animals observed were then averaged.
Real-time PCR
Total liver RNA was extracted with RNeasy minikit
(QIAGEN). cDNA was prepared as described (22). RT-PCR ex-
perimentswere done by SybrGreen andTaqMan technology using
the following primers: Fasn (forward, 5-cctctgatcagtggcctcctc-3;
reverse, 5-ggattcgggaatacaagtggc-3);Acly (forward, 5-gaagct-
gaccttgctgaaccc-3; reverse, 5-ccgtaattcgccagttcattg-3); Pmvk
(forward, 5-atggggctgtgatacagacag-3; reverse, 5-caaagttc-
ccaaagttgtcca-3); and 36b4 as reference gene (forward,
5-ggcgacctggaagtccaact-3; reverse, 5-ccatcagcaccacagccttc-3).
TaqMan gene expression assays for Foxo1 (Mm00490672_m1),
Igf-1 (Mm00439561_m1), and as a reference gene assay 18S
rRNA VIC-MGB-PDAR (Applied Biosystems by Life Technolo-
gies, Carlsbad, CA). The reaction was carried out according to the
manufacturer’s protocol using the 7900HT fast real-time PCR sys-
tem (Applied Biosystems by Life Technologies). Data were ana-
lyzed using the 2Ct method (23).
Statistical analysis
P values were calculated with one-way or two-way ANOVA
followed by Bonferroni post hoc test or t test with GraphPad
Prism version 5.02 for Windows (GraphPad Software, San
Diego, CA).
Results
ER transcriptional activity is not centrally
synchronized
We first investigated the extent to which ER activity
oscillated in intact and ovariectomized (ovx)mice. To this
aim, we measured luciferase-dependent photon emission
in nine intact and nine ovx mice for 21 d. In the cycling
mice (Fig. 1A), luciferase activity oscillatedwith time. The
amplitude of the oscillation was different in each body
area: for instance, it wasmore pronounced in hepatic than
the genital areaor limbs. Inmost bodyareas, the frequency
of oscillation appeared to be around 4 d (average in all
tissues 4.4d); this was expected, considering that in mice
the length of estrous cycle is 4–5 d; however, ER oscilla-
tions did not occur synchronously in all the body areas
(e.g. in the limbs the peak of photon emission was gener-
ally retarded by 1 d with respect to the hepatic and genital
areas that tended to oscillate in phase). Quite unexpect-
edly in these animals, ER activity fluctuated after ablation
of the ovaries with an oscillation period of about 4 d (Fig.
1B), but the amplitude of the oscillationwas lower than in
intactmice and the phasing among organswas altered: for
instance, photon emission in the hepatic and genital areas
was seldom in phase.
These results suggested that, in intact mice, ER activity
oscillateswitha frequency that is compatiblewith theestrous
cycle; however, 17-estradiol (E2) cannot be themaster reg-
ulatorofERoscillatoryactivitybecause theoscillationswere
asynchronous and persisted after ovariectomy.
2258 Della Torre et al. ER Oscillatory Activity Endocrinology, June 2011, 152(6):2256–2265
The measurement of mRNAs encoded by
endogenous ER target genes confirms that ER
activity is asynchronous in liver and bone of
intact mice
To assess the validity of the observation based on lu-
ciferase as an indicator of ER activity, we measured the
content of several endogenous genes in bone and liver dur-
ing the estrous cycle. The target genes were selected on the
basis of previous reports (24–26) and of studies carried
out in our laboratory (Stell A., personal communication).
First, we demonstrated that the genes selected were good
indicators of ER activity by measuring their mRNA con-
tent in tissue extracts of ovx mice treated with E2 for 6 h
at the dose of 10g/kg sc. This treatment was sufficient to
increase photon emission from 12,800 to 150,000 p/sec 
cm2 in liver (Fig. 2A); the effect of acute E2 treatment on
luciferase in bonewas less visible (Fig. 2C).Real-timePCR
analysis carried out with liver extracts showed that after
the E2 treatment, Foxo1 and Igf-1 mRNA were signifi-
cantly increased compared to controls (140 and31%,
respectively). This is in line with previous publications by
our and other laboratories. Conversely mRNAs such as
fatty acid synthase (Fasn;38%),ATP citrate lyase (Acly;
27%), and phosphomevalonate kinase (Pmvk;43%),
known to be encoded by genes repressed by ER, were
significantly decreased by the treatment (Fig. 2B). In bone,
the mRNAs encoding for Foxo1,Nrip1, and Bmp-6were
significantly increased by E2; in all experimental animals,
Igf-1 mRNA content appeared to be higher than in con-
trols, but the increase did not reach a statistically signifi-
cant value (Fig. 2D).Next,wemeasured luciferase activity
in 15 cycling ERE-Luc mice that were euthanized when
luciferase activitywas low in liver and high in bone (group
1) or, on the contrary, high in liver and low in bone (group
2) (Fig. 3, A and C). Real-time quantitative PCR analysis
demonstrated a full correspondence between the content
of the endogenous genes and luciferase activity as shown
in Fig. 3, B and D. Indeed, Fig. 3B shows that in liver the
genes induced by estrogens were low in group 1 (low liver
luciferase) and high in group 2 (high liver luciferase).
Conversely, the genes repressed by estrogenswere lower
in group 2 than in group 1. Similarly in bone (Fig. 3D),
in which the genes selected were all positively regulated
by E2, we observed that the mRNA content of Foxo1,
Nrip1, and Bmp-6 was higher in group 1 than in group
2. These results led us to conclude that luciferase is a
reliable indicator of ER transcriptional activity and can
be used as a surrogate target gene in our studies on the
effect of selected HT.
Tissue-specific action of selected HT in short-term
treatment (6 h)
The HT selected for the present study were: 1) natural
estrogens largely used in HT (Premarin or CE); 2) two
SERMs, BZA and RAL; and 3) TSEC (BZA together with
CE) (12, 13). The selection of the dosage to be adminis-
FIG. 1. Profile of photon emission in time in cycling and ovx ERE-Luc
mice. Photon emission was measured daily at 1500 h in 6-month-old
ERE-Luc mice cycling or ovariectomized 3 wk before the initiation of
the study. Each animal group was constituted of nine mice. The figure
represents daily photon emission (plotted as photons per second per
square centimeter) in head, genital, and hepatic areas of a single
mouse representative of the pattern of ER activity in intact (A) and ovx
(B) female mice.
FIG. 2. Luciferase activity in selected tissues of ERE-Luc mice and
relative endogeneous gene target expression after acute treatment
with E2. Photon emission in the hepatic area (A) and in limbs (C) was
measured by a 5-min exposure time to a CCD camera (see Materials
and Methods) in mice at 6 h after treatment with 10 g/kg of E2 or
vehicle (ctrl). After the imaging session, mice were euthanized and
tissues rapidly dissected. B, Foxo1, Igf-1, Fasn, Acly, and Pmvk mRNA
content in liver of control and E2-treated mice. D, Foxo1, Igf-1, Nrip1,
and Bmp-6 mRNA content in bone of control and E2-treated mice.
Columns represent means  SEM of groups of six mice each. *, P 
0.05; **, P  0.01. P values were calculated with t test.
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tered with regard to CE, BZA, and RAL was based on
previous reports (27). Before starting the long-term study
with the different types of HRT currently in use, we dem-
onstrated their ability to regulate the luciferase reporter
when administered orally at a dosage previously found to
mimicHT in humans (10, 11, 15, 27). For the TSEC treat-
ment, we tested two different concentrations of BZA (2
and 10mg/kg) to identify the concentration necessary and
sufficient to block CE effects when used in the combined
therapy.
The study was carried out in ovx ERE-Luc mice at 2–3
months of age; surgery was performed 3 wk before HT.
Two weeks after surgery, circulating levels of estradiol
were undetectable (not shown) and the uterus weight was
significantly decreased (73% vs. proestrus, the phase of
the reproductive cycle during which estrogen circulating
levels are highest) (Supplemental Fig. 1A, published on
TheEndocrine Society’s JournalsOnlineweb site at http://
endo.endojournals.org). Ovarian ablation reduced signif-
icantly ERactivity on the reporter gene (Supplemental Fig.
2), yet the persistence of luciferase pointed to the existence
of factors other than ovarian estrogens able to elicit ER
activity.
Six hours after treatment, CE induced a strong tran-
scriptional activity of ER in the hepatic and genital areas
(Supplemental Fig. 1, B and C). With other treatments, a
trend to increasewas observed in several of the areas stud-
ied, but none of the changes reached statistical signifi-
cance. These results were confirmed by a more quantita-
tive study in which luciferase activity was directly
measured in tissue extracts (Supplemental Fig. 3): in CE-
treatedmice, luciferase activitywas increased in the uterus
(550%), breast (230%), liver (3451%), and bone
(145%). The high, but not the low, concentration of
both SERMs caused an increased ER activity in the breast
(BZA, 289%; RAL, 286% vs. vehicle); RAL at both
dosages was able to increase ER activity in the intestine
(159%). In this short-term study, BZA andRAL did not
increase ER activity in bone despite the well-known pro-
tective effects of the two compounds against ovx-induced
osteoporosis.
This preliminary study established that the sensitivity
of the bioluminescence imaging was sufficient to investi-
gate the effects of the treatments.
Long-term 21-d effect of HT with CE, SERM,
or TSEC
For the long-term study, ovxmicewere treated daily by
gavage with CE (3 mg/kg); BZA (10 mg/kg); TSEC (CE 3
mg/kg BZA 10mg/kg), and RAL (10 mg/kg). Details of
the treatments are described in the methodology section.
Photon emission at 3, 7, 14, and 21 d of treatment (Fig. 4,
A and B) indicated the efficacy of eachHT in specific body
areas. In line with the short-term treatment, CE signifi-
cantly increased ER activity in the genital area (up to
318% vs. vehicle at d 7); this effectwas blocked byBZA.
In this body area, SERM affected ER activity only tran-
siently (d 14). Measurement of the uterus weight in long-
term-treated animals further supported the lack of estro-
genic effects of BZA, RAL, and TSEC in this organ
(Supplemental Fig. 4). In limbs, CE and BZAwere able to
significantly increase ER activity transiently (CE, 98%
at d 7 and BZA, 105% at d 3); although a trend to an
increase was present all through out the study, TSEC had
a strong effect augmenting ER activity in limbs from d 3
until the end of the treatment (d 3:111%; d 7:120%;
d 14: 118%; d 21: 101%), and RAL had a delayed
effect (d 14:88%), which lasted to d 21 (70%). In line
with previous reports of estrogens in liver (14), CE had a
major effect in the hepatic area that was blocked by BZA;
BZA andRAL alone did not affect ER activity in this body
region. Interestingly, in the hepatic area, but not in the
genital area, the response to CE decreased with time, sug-
gesting a tissue-specific mechanism diminishing ER activ-
ity upon prolonged stimulation. We failed to see any sig-
nificant change in the abdominal area with the exception
of TSEC, which had a delayed effect (d 21:160%). The
study of luciferase enzymatic activity in the tissues dis-
sected from the animals at the end of the treatment (Sup-
plemental Fig. 5) fully supported the in vivo data indicat-
FIG. 3. Comparative analysis of luciferase activity mice and
endogeneous gene target expression in selected tissues of intact ERE-
Luc. Photon emission in the hepatic area (A) and limbs (C) of mice of
group 1 (low liver/high bone photon emission) and group 2 (high liver/
low bone photon emission). B, Foxo1, Igf-1, Fasn, Acly, and Pmvk
mRNA content measured by real-time quantitative PCR in tissue
extracts of liver of group 1 and group 2 mice. D, Foxo1, Igf-1, Nrip1,
and Bmp-6 mRNA content in bone of mice belonging to group 1 and
group 2. Columns represent means  SEM of groups of six mice each.
*, P  0.05; **, P  0.01; ***, P  0.001. P values were calculated
with t test.
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ing that after 21 d of treatment, ER activity was still
elevated in the uterus (435%) and the liver (868%) of
mice treated with CE and in the bone (64%) and the
intestine (333%) of those exposed to TSEC.
The observation that during the long-term treatment,
photon emission appeared to decrease with time in the
hepatic area but not in the genital area and limbs and that
in selected areas the changes were transient, led us to fur-
ther investigate the dynamics of ER activity by measuring
photon emission daily.
Dynamics of ER activity during HT
To obtain amore detailed knowledge of ER spatiotem-
poral activity, we measure photon emission daily in ovx
mice treated as before and in intact, cycling mice. Despite
the expected variability among individuals, luciferase ac-
tivity appeared to oscillate in time with an amplitude and
a frequency dependent on the type of treatment and the
tissue taken in consideration (Fig. 5). The application of
Fourier transform for the analysis of the effect of each
treatment on ER activity in time showed that ovariectomy
reduced the amplitude of the ER oscil-
lations in the bone (head, 70% and
limb, 22%, ovx vs. cycling), genital
(59%), and hepatic (39%) areas
but not in the abdominal area.CE treat-
ment increased significantly the ampli-
tude of photon emission in the genital
(90%) and hepatic areas (481%)
but in thebone andabdominal areawas
not able to restore the amplitude of os-
cillation observed in intact mice. The
effect of BZA, TSEC, and RALwas not
significant in anyof the areas taken into
consideration, even if a trend to in-
creasewas observedwith TSEC in head
(29% and 62%, respectively) (Fig.
6A). On the other hand, OVX de-
creased significantly the period of ER
oscillation in the hepatic (14%) and
abdominal areas (23%). Only TSEC
was able to reverse this effect in the he-
patic area (55% vs. ovx). In the bone
areas, the effect of the treatments var-
ied: CE increased the period in the limb
(88% vs. ovx) but decreased it in the
head (31%), whereas TSEC and RAL
decreased the period in the limb (31
and27% vs. ovx, respectively) but did
not affect the head. Only CE decreased
the ERperiod of oscillation in the genital
area (20% vs. ovx) (Fig. 6B).
Is ER oscillatory activity relevant for the
tissue-specific activity of the receptor?
The above results did not point to a straightforward
relationship between changes in the amplitude and period
of ER transcriptional oscillation and the therapeutic effi-
cacy of the compounds tested. For instance, the decreased
amplitude observed in the skeletal tissues with ovx might
suggest a relationship between cycle amplitude and ER
state of activity. However, in ovx mice, compounds like
RAL and BZA, known to protect against ovx-induced
bone loss, were unable to rescue the amplitude of oscilla-
tion observed in the head and limbs of cycling animals.
With respect to the period of oscillation, no differencewas
observed in the skeletal and genital areas between ovx and
intact animals, suggesting that this parameter was not in-
dicativeof the efficacyofERactivity in those tissues.These
observations suggested that other parameters should be
taken into consideration for the identification of the com-
poundsable to reinstate thebeneficial effects of thenatural
estrous cycle. In view of the large number of tissues in
FIG. 4. Photon emission of selected areas of ERE-Luc mice undergoing HT. A, Pseudocolor
image of photon emission from one representative animal/group at 0, 3, 7, and 21 d of
chronic oral treatment with vehicle, CE (3 mg/kg), BZA (10 mg/kg), TSEC (BZA 10 mg/kg  CE
3 mg/kg), and RAL (10 mg/kg). B, Photon emission measured as photons per second per
square centimeter from specific body areas. Data represent mean  SEM of three groups of
three animals (total nine animals/group). *, P  0,05; **, P  0,01; ***, P  0,001 vs.
vehicle; °°, P  0,01; °°°, P  0,001 vs. CE. P values were calculated with two-way ANOVA
followed by Bonferroni post hoc test.
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whichER is active,we speculated that thebeneficial effects
of the hormone are due to a harmonic sequence of events
in which the relative synchronization of ER activity in the
different tissue is critical. We tried to test this hypothesis
by counting thenumberof synchronous cycles in twobody
areas at the time during the 21 d of the experiment (Fig. 7).
We reasoned that during the estrous cycle, the body areas
representing functionally related tissues should cycle in
synchrony. Indeed, in the skeletal areas (photon emission
from head and limb) of cycling mice, the percentage of
synchronic cyclingwas generally quite high (76.5%); also,
reproductive (breast and genital area) and genital and he-
patic areaswere cycling relatively in phase (56 and55%of
the cycles were in phase, respectively). The latter obser-
vation had been previously reported (14). In the hepatic
and abdominal areas, the percentage of synchrony was
significantly lower (29.7%).
Ovariectomy had a disruptive effect by decreasing the
extent of synchronous phasing in the hepatic and abdom-
inal areas (from 29.7 to 16%) and in the genital and he-
patic area (from 55 to 28%). No significant change was
observed in the skeletal and reproductive areas, whereas a
trend to an increased phasing was measured in the head
and genital areas.
Among HT, only TSEC and BZA were able to com-
pletely rescue the effect of ovx in the phasing between
hepatic and abdominal areas (from 16 to 35 and 34%,
respectively).
AllHT, includingCE, tended to decrease the synchrony
of cycling of reproductive areas (from 57% to CE, 31%;
TSEC, 32%; BZA, 40%; RAL, 40%). A trend to increase
in the synchronic oscillation among skeletal tissues was
observed with TSEC (from 67 to 84%), BZA (to 81%),
and RAL (to 76%). When we compared head and genital
areas, the only significant change was observed with the
CE treatment that increased the phasing with respect to
cycling mice (138%).
Discussion
Pulsatility characterizes the secretion of several hormones
(e.g. GH, GnRH, insulin), and the maintenance of a spe-
FIG. 5. Profile of photon emission in time in ERE-Luc mice undergoing
HT. Photon emission was measured daily in head, limbs, and genital,
hepatic, and abdominal areas at 1500 h (6 h after the treatment) using
a segmentation algorithm (22). The experiment was done in
experimental groups each composed of nine mice. Graphs reproduce
data obtained from a single, representative mouse/group.
FIG. 6. Fourier transform (FT) analysis of the profile of ER activity in
time to measure the amplitude and frequency of luciferase oscillation
in different body areas of ERE-Luc intact (cyc) and ovx mice and in ovx
mice with HT. FT was applied to the data described in Figs. 4 and 5. A,
Average amplitude of cycles in each group of nine mice estimated by
measuring the degree of displacement from the resting state
(calculated as the square root of the 95th percentile of the power
spectra). cyc, Cycling mice (or intact mice). B, Period of oscillation
estimated by the inverse of the frequencies under the amplitude
previously calculated. Bars represent average  SEM of groups of nine
mice each. *, P  0.05; **, P  0.01 vs. cycling animals; °, P  0.05;
°°, P  0.01 vs. ovx mice. P values were calculated with one-way
ANOVA followed by Bonferroni post hoc test.
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cific pattern of secretion is necessary for the hormone full
endocrine effects (25–28). This may be valid also for es-
trogens; indeed, current view predicts that a finely tuned
feedback system in the hypothalamic-pituitary-gonadal
axis ensures the maintenance of the reproductive cycle
regulated by the cyclic synthesis of ovarian sex hormones
and the activation of ER transcriptional activity in repro-
ductive as well as nonreproductive organs. The observa-
tions reported here argue against such a unicentric model
of ER regulation because it is shown that: 1) in intact mice
the systemic production of estrogens by the ovaries fails to
synchronize ER activity among target organs; 2) after
ovariectomy ER maintains a cyclic activity; and 3) each
organ regulates autonomously the frequency and the am-
plitude of ER transcriptional activity in response to the
administrationof estrogensof different chemical natureor
of a combination of estrogenic compounds.
At the present time, the mechanisms underlying the
long-paced, rhythmic oscillation of ER activity as well as
its physiological function may be only object of specula-
tion. Western blot analysis and RT-PCR carried out on
liver and uterus extracts show that during the long-paced
ER transcriptional oscillation, the content of the receptor
protein and mRNA is unchanged (not shown). Thus, we
do not believe that the oscillation described here is a con-
sequence of ER down-regulation.
The observation that the phasing of the oscillation is
independent from a central control and is very susceptible
to the nature of circulating estrogens may suggest that in
each cell the ER activity is controlled autonomously via
interlocking transcription/translation feedback loops.
This would be in line with what reported for the rhythmic
fluctuationsof the circadiangenes,whichappear tobeable
to oscillate independently from the cen-
tral oscillator located in the suprachias-
matic nucleus (28–30). Further support-
ing the hypothesis of cell autonomous
regulatorymechanismsare recent studies
carriedout in isolatedcells inwhichitwas
demonstrated that, in the constant pres-
ence of the ligand, ER activity fluctuates
rapidly (in the order of minutes). The
mechanisms driving the receptor oscilla-
tory activity include changes in coregula-
tor recruitment (31), assembly of the
components of the preinitiation complex
(32), and posttranslational regulation of
the receptor leading to proteolysis of the
ER complex (33). These oscillations are
believed to be necessary to poise the re-
ceptors for a proper response to hor-
monal stimulus.
The fluctuations of ER activity de-
scribed here have a periodicity very similar to the estrous
cycle (4.4 d as average in the different tissues of cycling
mice) yet are not synchronized on the fluctuations of the
sex hormones in the blood stream. Because it is well
known that several nonsteroidal stimuli may activate ER
transcriptionally (15, 34–38), it is tempting to speculate
that endocrine factors other than ovarian estrogen are re-
sponsible for the waves of receptor activation observed in
the different ER-expressing cells. Supporting this hypoth-
esis is a recent study on mice carrying a liver-selective ab-
lation of ER (39) in which it was demonstrated that he-
patic ER play amajor role in the synthesis and secretion of
Igf-1, a liver hormone essential for several physiological
functions including the maturation of the uterus epithe-
lium and the full execution of the reproductive cycle. Con-
sidering the major involvement of ER in reproductive
functions, a decentralized control of the activity of these
receptors would serve the purpose to grant the reciprocal
regulatory feedbacks to ensure that reproductionoccurs in
the most favorable energetic/metabolic/health conditions
and to enable the significant metabolic adaptations asso-
ciated with changes in the reproductive status (e.g. pu-
berty, pregnancy, lactation). It is conceivable that in each
target tissue the significant changes in estrogen synthesis
and metabolism reported in different reproductive condi-
tionsare instrumental tomodulate large transcriptionpro-
grams that trigger themetabolic responsenecessary for the
successful reproduction. Several studies have underlined
the relevance of the chemical stimulus triggering ER ac-
tivity for the selection of the genes to be transcribed (40–
43). We also showed by chip-on-chip analysis (data not
shown) that in liver, ER associated with very distinct
FIG. 7. Effect of HT on the phasing of luciferase oscillation among different body areas of
living ERE-Luc mice. The number of synchronous cycles/total cycles in the 21-d observation
period was scored analyzing the profile of ER activity of the body areas of each single animal.
Data represent the average percentage of synchronic cycling in four clusters of anatomical
regions: skeletal area (head and limbs), reproductive area (breast and genital area), hepatic-
abdominal areas, reproductive-hepatic areas, and head-genital areas. The experiment was done
in experimental groups each composed of nine animals. cyc, Cycling mice (or intact mice).
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classes of promoters during the different phases of the
estrous cycle. On the other hand, the ability of factors
other than estrogens to regulate ER activity may be re-
quired to prevent pregnancy in case of disease or insuf-
ficient nutritional contribution. According to this view
and in agreement with the results of the present study,
the nature of the estrogenic stimulus may act as a trigger
for the differential, rhythmic, and harmonic modula-
tion of ER in the different organs necessary for the ac-
tivation of the gene programs fulfilling the necessary
metabolic program.
It remains to be established which is the hormonal set-
ting that needs to be reestablished in the case of HT in the
postmenopause. The study indicated that the use of SERM
or a combination of natural hormones and SERM may
have a significant effect on the relative phasing and inten-
sity of ER activity in the target organs; this prospects the
possibility to reproduce pharmacologically the desired
complexity of ER action in the whole organism. What is
lacking at the present time is a clear view of the pattern of
ER activity that would have the most favorable effects for
women’s health during aging. In the absence of such
knowledge, we believe that themere analysis of the effects
ofHRT on a single parameter (e.g. the effect on the period
or amplitude of ER activity in different organs) is not suf-
ficient to establish the superiority of a treatment onothers.
In a recent study, Rando et al. (44) applied an algorithm
developed for the comparative analysis ofmultivariate pa-
rameters to the study of the activity of synthetic ER li-
gands. Most interestingly, the study showed that the ap-
plication of such an algorithm enables the identification of
structurally related compounds by comparing their spa-
tiotemporal effects on theERE-Lucpromoter. In addition,
the study showed that the method enables one to measure
the ability of each family of compounds to reproduce the
state of activation of ER that characterize the intact, cy-
cling mouse. We believe that these methodologies may, at
the present time, facilitate the identification of HT to be
applied.
Our current hypothesis that the hierarchical ER acti-
vation in different tissues is a mechanism set in evolution
to enable ER to recognize the changes in the reproductive
status and to alert and adapt the entire organism to the
novel energetic requirements may help in a better under-
standing of the metabolic changes occurring after meno-
pause and in devising novel, more efficacious therapeutic
interventions.
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